TY - JOUR
T1 - Adoptive T cell therapy
T2 - points to consider
AU - Yee, Cassian
N1 - Publisher Copyright:
© 2018
PY - 2018/4
Y1 - 2018/4
N2 - Adoptive Cell Therapy (ACT) has enjoyed a revival in recent years with the approval of CAR T cells for the treatment of patients with B cell malignancies. Advancing the use of adoptively transferred T cells for the treatment of patients with solid tumor and other hematologic malignancies however, will require addressing numerous effector cell intrinsic as well as tumor micro environmental hurdles and exploiting a broader ACT platform that includes not only engineered CAR-T cells, but also other forms of ACT including Endogenous T Cell (ETC) and Tumor-infiltrating Lymphocyte (TIL) therapy. In this review, we open this discussion with some ‘points to consider’ as a starting point for envisioning more effective strategies that are now feasible because of recent discoveries In immune resistance and the development of enabling technologies to harness the power of tumor - reactive T cells for adoptive cell therapy.
AB - Adoptive Cell Therapy (ACT) has enjoyed a revival in recent years with the approval of CAR T cells for the treatment of patients with B cell malignancies. Advancing the use of adoptively transferred T cells for the treatment of patients with solid tumor and other hematologic malignancies however, will require addressing numerous effector cell intrinsic as well as tumor micro environmental hurdles and exploiting a broader ACT platform that includes not only engineered CAR-T cells, but also other forms of ACT including Endogenous T Cell (ETC) and Tumor-infiltrating Lymphocyte (TIL) therapy. In this review, we open this discussion with some ‘points to consider’ as a starting point for envisioning more effective strategies that are now feasible because of recent discoveries In immune resistance and the development of enabling technologies to harness the power of tumor - reactive T cells for adoptive cell therapy.
UR - http://www.scopus.com/inward/record.url?scp=85046552747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046552747&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2018.04.007
DO - 10.1016/j.coi.2018.04.007
M3 - Review article
C2 - 29730057
AN - SCOPUS:85046552747
SN - 0952-7915
VL - 51
SP - 197
EP - 203
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -